← Back to Search

Behavioural Intervention

Attentional-Control Training for Sickle Cell Disease (ACT Trial)

N/A

Recruiting

Led By Steven J Hardy, Ph.D.

Research Sponsored by Children's National Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 10 months

Awards & highlights

ACT Trial Summary

This trial is studying the effectiveness of a game-like program to help children with sickle cell disease improve their attention.

Eligible Conditions

Sickle Cell Disease
Attention Deficit Disorder

ACT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 10 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 10 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

EndeavorRx feasibility assessed by patient/family interest

EndeavorRx feasibility assessed by program completion rates

EndeavorRx feasibility assessed by reports of technical ease-of-use and satisfaction

Secondary outcome measures

Inattention assessed by change in Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3)

Inattention assessed by change in the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V)

ACT Trial Design

1Treatment groups

Experimental Treatment

Group I: EndeavorRxExperimental Treatment1 Intervention

Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Children's National Research InstituteLead Sponsor

213 Previous Clinical Trials

209,217 Total Patients Enrolled

Steven J Hardy, Ph.D.Principal InvestigatorChildren's National Research Institute

Media Library

EndeavorRx (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05099874 — N/A

Sickle Cell Disease Research Study Groups: EndeavorRx

Sickle Cell Disease Clinical Trial 2023: EndeavorRx Highlights & Side Effects. Trial Name: NCT05099874 — N/A

EndeavorRx (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05099874 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial include elderly participants?

"This clinical trial requires that patients are between 8 and 16 years of age. There is an abundance of similar studies for minors (148) as well as seniors (648)."

Answered by AI

What is the uppermost threshold of participants in this clinical trial?

"Affirmative. According to the information posted on clinicaltrials.gov, this medical trial is recruiting patients. The investigation was first published in December of 2022 and has recently been updated in June 2023. Currently 1 site requires 20 participants for enrollment into the study."

Answered by AI

Can I be admitted to participate in this clinical experiment?

"To qualify for this clinical trial, aspirants must have sickle cell disease and be between the ages of 8 to 16. Approximately 20 participants are needed in total."

Answered by AI

Does this research program currently have open enrollment?

"Affirmative. According to records found on clinicaltrials.gov, this experiment is currently recruiting volunteers; it was first made available for public viewing on December 20th 2022 and underwent its most recent update on June 23rd 2023. At present, the trial seeks out twenty participants from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Steven J. Hardy 2022. "Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05099874.

All > Sickle Cell Disease > Sickle Cell